- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04087889
Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
Individual Patient Expanded Access IND of Hope Biosciences Allogeneic First Blood Relative Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Once the eligibility is confirmed, approximately 1-3 weeks after the screening/baseline visit, the subject will return for the first infusion. Subsequent treatments will occur weekly for the first 8 infusions, followed by 4 infusion that occur 2 weeks apart. The total number of infusions will be 12.
On each of these visits, the subject will receive one allogeneic HB-adMSC infusion of 200 million (2 x 10^8 cells) total cells suspended in 250 mL normal saline for IV infusion. Every infusion visit will include the following procedures:
- Review of medical history,
- Complete Physical exam (Week 1, 4, 10, 20, and 52),
- Vital signs (Heart Rate, BP, Respirations, Temp., SpO2),
- Weight measurement
- A verification of patient consent will be verbally performed
*When applicable (Week 4, 7, 10, 14, 20 and 52): A urine and blood sample for clinical labs including:
- CBC with diff.,
- CMP,
- Coagulation Panel,
- TNF-a
- IL-6
- CA 19-9
- LDH
- The HB-adMSC infusion will be given via IV.
- The subject will then be monitored for a minimum of 2hr after infusion.
- 24-hour telephone assessment for adverse events
- Video Documentation
Vital signs will be continuously monitored during the infusion and recorded at 15 minutes intervals during the first hour. Vital signs will be recorded at the end of the infusion and every 30 minutes x 2 hours or more frequently if clinically indicated. The subject will be contacted by telephone 24hr. after the infusion visit to determine if any adverse events have occurred.
*Please note that blood and urine sample during the intervention period will only be required for the visits corresponding to weeks 4, 7, 10, 14, 20 and 52. During these visits, these samples will always be taken before the infusion is started. Refer to Table 1. Schedule of assessments for more details.
Follow-up Visits week 4,7, 10, 14, 20, and 52
The subject will undergo the following procedures at each follow-up visit without infusion:
- Review and update medical history,
- Update concomitant medications list
- Weight
- Vital signs (Heart Rate, BP, Respirations, Temp., SpO2),
- Complete physical exam (Week 1, 4, 10, 20, and 52)
A urine and blood sample for clinical labs including:
- CBC with diff.,
- CMP,
- Coagulation Panel,
- TNF-a
- IL-6
- CA 19-9
- LDH
- Adverse event monitoring.
In addition, visits 13 and 14 (week 20 and 52) will include CT Scans of the chest, abdomen and pelvis. This procedure could be done up to 7 days before or after the actual visit day, depending on availability and schedule of the imaging center. If a CT Scan has been done as standard of care within 30 days of these visits, it would meet the requirement for this assessment.
Studietyp
Utökad åtkomsttyp
- Individuella patienter
Kontakter och platser
Studieorter
-
-
Texas
-
Sugar Land, Texas, Förenta staterna, 77478
- Hope Biosciences
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Documented diagnosis of Pancreatic Cancer
- Hemodynamically stable
Exclusion Criteria:
- Immunosuppression as defined by WBC < 3, 000 cells/ml at baseline screening.
- Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSC administration.
- Any abnormal, inexplicable laboratory result with no obvious cause defined.
- Participation in other interventional research studies. Unwillingness to return for follow-up visits
Studieplan
Hur är studien utformad?
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HBPC01
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bukspottskörtelcancer
-
Tianjin Medical University Cancer Institute and...Har inte rekryterat ännuPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekryteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekryteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Cedars-Sinai Medical CenterRekryteringPDAC - Pancreatic Ductal AdenocarcinomaFörenta staterna
-
Azienda Ospedaliera Universitaria Integrata VeronaRekryteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Radboud University Medical CenterDutch Cancer SocietyRekryteringPDAC - Pancreatic Ductal AdenocarcinomaNederländerna
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... och andra samarbetspartnersRekryteringBukspottskörtelcancer | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannien
-
Chinese PLA General HospitalRekryteringPankreatiska neoplasmer | Bukspottskörtelcancer | Bukspottkörtelcancer | PDAC - Pancreatic Ductal AdenocarcinomaKina
-
Andrei IagaruInte längre tillgängligKarcinoida tumörer | Islet Cell (Pancreatic NET) | Andra neuroendokrina tumörerFörenta staterna
-
Mayo ClinicRekryteringBukspottskörtelcancer | Duktalt adenokarcinom i bukspottkörteln | PDAC | PDAC - Pancreatic Ductal AdenocarcinomaFörenta staterna
Kliniska prövningar på HB-adMSCs
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesInte längre tillgängligKronisk smärtaFörenta staterna
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesInte längre tillgängligIndividuell patient utökad tillgång IND för autolog HB-adMSCS för behandling av bilateral knäsmärta.Osteo Artrit Knä | Knäsmärta kroniskFörenta staterna
-
Hope Biosciences Stem Cell Research FoundationHope Biosciences; United Memorial Medical Center; River Oaks Hospital and...AvslutadCovid-19Förenta staterna
-
University Hospital, ToulouseRekryteringSystemisk sklerosFrankrike
-
Medical University of WarsawOkändArtros | Knäartros | Höftartros | Glenohumeral artrosPolen
-
Johnson & Johnson Pte LtdShanghai China-Norm Management Consulting co.,LTD; Shanghai Skin Disease...Avslutad
-
Hookipa Biotech GmbHRekryteringHPV-relaterat skivepitelcancerFörenta staterna, Spanien, Nederländerna
-
Dr. Soetomo General HospitalOkändBrachial Plexus NeuropatierIndonesien
-
Hope BiosciencesThe University of Texas Health Science Center, HoustonAktiv, inte rekryterande
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesInte längre tillgängligMellanstor patientpopulation Expanded Access IND för behandling av patienter med Parkinsons sjukdom.Parkinsons sjukdomFörenta staterna